All In Biotech

Drug Trial Radar · NCT03547271

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Last checked: Nov 20, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,660 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,660

Actual

Start

Dec 14, 2018

Primary completion

May 17, 2023

Study completion May 24, 2023

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jun 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary objective: This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b \[DTaP-IPV-HB-Hib vaccine\]) to infants and toddlers 6 weeks to 18 months old Secondary objectives: This study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old. \- This study aimed to describe the Ab responses against meningococcal groups A, C, Y, and W and the antigens of the routine pediatric vaccines administered in the study.

Conditions

  • Meningococcal Infections

Interventions

  • MenACYW conjugate vaccineBiological

    Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular

  • Meningococcal group A, C, W-135, and Y conjugate vaccineBiological

    Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular

  • DTaP-IPV-HB-Hib vaccineBiological

    Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

  • Pneumococcal vaccine (13-valent)Biological

    Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

  • Pneumococcal vaccine (10-valent)Biological

    Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)

  • MMR vaccineBiological

    Measles, mumps, and rubella vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and YTime frame: At 30 days post Dose 3 [12 to 18 months of age (MoA)]

Locations

33 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 2031006

    Chlumec nad Cidlinou, Czechia

  • Investigational Site Number : 2031013

    Domažlice, Czechia

  • Investigational Site Number : 2031010

    Jindřichův Hradec, Czechia

  • Investigational Site Number : 2031012

    Jindřichův Hradec, Czechia

  • Investigational Site Number : 2031003

    Ostrava, Czechia

  • Investigational Site Number : 2031008

    Ostrava-hrabuvka, Czechia

  • Investigational Site Number : 2031009

    Pardubice, Czechia

  • Investigational Site Number : 2031005

    Pardubice, Czechia

  • Investigational Site Number : 2031007

    Smiřice, Czechia

  • Investigational Site Number : 2462007

    Espoo, Finland

  • Investigational Site Number : 2462003

    Helsinki, Finland

  • Investigational Site Number : 2462004

    Helsinki, Finland

  • Investigational Site Number : 2462001

    Jarvenpaa, Finland

  • Investigational Site Number : 2462006

    Kokkola, Finland

  • Investigational Site Number : 2462005

    Oulu, Finland

  • Investigational Site Number : 2462002

    Pori, Finland

  • Investigational Site Number : 2462009

    Seinäjoki, Finland

  • Investigational Site Number : 2462010

    Tampere, Finland

  • Investigational Site Number : 2462008

    Turku, Finland

  • Investigational Site Number : 3803002

    Milan, Italy

  • Investigational Site Number : 6167003

    Siemianowice Śląskie, Poland

  • Investigational Site Number : 6167006

    Torun, Poland

  • Investigational Site Number : 6167002

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Investigational Site Number : 6167004

    Trzebnica, Lower Silesian Voivodeship, Poland

  • Investigational Site Number : 6424003

    Brasov, Romania

  • Investigational Site Number : 6424001

    Bucaresti, Romania

  • Investigational Site Number : 6424002

    Calarasi, Romania

  • Investigational Site Number : 6424006

    Caracal, Romania

  • Investigational Site Number : 7245002

    Madrid, Spain

  • Investigational Site Number : 7245001

    Santiago de Compostela, Spain

  • Investigational Site Number : 7245006

    Seville, Spain

  • Investigational Site Number : 7245003

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7526001

    Umeå, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.